Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients : Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ClinicalTrials.gov - (2023) vom: 28. März Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 8, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 05, 2023, Last updated: April 05, 2023 |
|---|
| Study ID: |
NCT04379817 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003385248 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003385248 | ||
| 003 | DE-627 | ||
| 005 | 20230425202231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003385248 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04379817 | ||
| 035 | |a (UBBS_Klinische_Studien)IJBMNSSTR | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients |b Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 8, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 05, 2023, Last updated: April 05, 2023 | ||
| 520 | |a This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide. | ||
| 650 | 2 | |a Multiple Myeloma | |
| 650 | 2 | |a Neoplasms, Plasma Cell | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Recruiting | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 28. März |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:03 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04379817 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 03 | ||